Skip to main content
MMedVellum
MCQsExamsAtlas
DashboardPricing
MMedVellum

The exam atlas that feels like a flagship product — evidence-graded topics and exam tools for MBBS and fellowship preparation. Built to scale to fifty specialties. Educational content only — not medical advice.

llms.txt·psychiatry LLM catalog · sitemap

Atlas

  • Specialty atlas
  • MBBS / Core medicine
  • Dermatology
  • ICU Fellowship (CICM)
  • Anaesthesia
  • Emergency Medicine
  • Psychiatry Fellowship

Study & account

  • MCQ practice
  • Practice alias
  • Exam tools
  • Dashboard
  • Pricing
  • Sign in

© 2026 MedVellum. For education only — not a substitute for clinical judgement.

Clinical Atlas Prestige · Evidence-first

Psych CASC / OSCEPsychopharmacology — cognitive enhancers

Psych CASC / OSCE · Psychopharmacology — cognitive enhancers

Explaining donepezil and expectations to a carer (CASC)

CASC-style communication station: realistic benefit counselling, AD2000 appraisal without nihilism, memantine timing, GI management, and shared monitoring plan.

communication
On this page & tools

Target exams

FRANZCPMRCPsychABPNMD-DNB

Target exams

FRANZCPMRCPsychABPNMD-DNB
Prompt
Daughter of a 76-year-old man newly diagnosed with mild Alzheimer disease wants 'the tablet that stops dementia'. She has read that donepezil is 'useless' (AD2000 headlines) and also asks whether to start memantine and donepezil together today. Father has mild nausea on a trial of donepezil 5 mg started by the GP.

Station instructions (candidate)

You have 7 minutes with the daughter. Explain what donepezil can realistically achieve, address the AD2000 “useless drug” narrative without dismissing her reading, manage mild nausea, explain why dual memantine start is not automatic in mild disease, and agree a monitoring plan including when combination or stopping might be discussed later. Do not guarantee cure. Do not force treatment. Use plain language and check understanding.[1][2][5]

Marking domains

Empathy and agenda; accurate plain-language explanation of symptomatic (not curative) benefit; balanced AD2000 critical appraisal; correct mild-stage preference for AChEI before routine memantine; practical nausea advice and safety netting (syncope, severe vomiting); collaborative review plan; offers written information and questions.[1][2][3][6]

Model communication map

  1. Open: thank her; check what she has been told about the diagnosis and what “stop dementia” means to her.[5]
  2. Realistic benefit: donepezil can modestly help memory and everyday thinking for some people and may slow decline a little — it does not reverse Alzheimer disease or remove the need for support and safety planning.[1][5]
  3. AD2000 narrative: one large UK study found less benefit on some long-term disability outcomes and sparked debate; other trials and reviews still show average small benefits — we individualise rather than declare the drug universally useless or magical.[2][5]
  4. Nausea now: common early effect; take with food if appropriate, ensure hydration; if mild and improving, often continue; if severe vomiting, weight loss, or fainting — hold and call us/GP/ED as directed.[5]
  5. Memantine timing: usually considered more when disease is moderate–severe (or per specialist pathway); combination evidence (Tariot) is mainly in that setting; DOMINO-AD later supports not auto-stopping donepezil just because things get harder.[3][4][6]
  6. Plan: review soon for side-effects; later review for whether 10 mg is appropriate after enough time on 5 mg; share emergency symptoms; invite questions; written leaflet.[1][5]

Common fails

  • Promising cure or “stops dementia completely.”[5]
  • Agreeing donepezil is proven useless solely from AD2000 headlines.[2]
  • Starting memantine dual therapy as mandatory in mild AD without rationale.[4][6]
  • Ignoring nausea safety-netting or cardiac red flags.[5]
  • Lecturing without checking her goals and understanding.[5]

References

  1. [1]Rogers SL, Farlow MR, Doody RS, et al. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease Neurology, 1998.PMID 9443470
  2. [2]Courtney C, Farrell D, Gray R, et al. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial Lancet, 2004.PMID 15220031
  3. [3]Howard R, McShane R, Lindesay J, et al. Donepezil and memantine for moderate-to-severe Alzheimer's disease N Engl J Med, 2012.PMID 22397651
  4. [4]Tariot PN, Farlow MR, Grossberg GT, et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial JAMA, 2004.PMID 14734594
  5. [5]Birks JS, Harvey RJ Donepezil for dementia due to Alzheimer's disease Cochrane Database Syst Rev, 2018.PMID 29923184
  6. [6]Reisberg B, Doody R, Stöffler A, et al. Memantine in moderate-to-severe Alzheimer's disease N Engl J Med, 2003.PMID 12672860